A Three-part First-in-human Trial to Assess Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of GUB-UCN2 in Healthy Lean and Obese Participants and Participants With T2D
A phase 1/2 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 188 participants.
Also called NCT07702890
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; double masking; primary purpose treatment
- Phase
- Phase 1/2
- Enrolled
- 188 participants
- Sponsor
- Gubra A/S
- Registry
-
NCT07702890 -
2025-524921-42-00
-
- Started
- (actual)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- Germany
- Registry status
- Recruiting
Technical summary
Registry record NCT07702890. Randomized; double masking; primary purpose treatment. Start 2026-07-27 (actual); primary completion 2028-12 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- A Three-part First-in-human Trial to Assess Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of GUB-UCN2 in Healthy Lean and Obese Participants and Participants With T2D
- Condition
- Obesity
- Condition
- Type 2 Diabetes
- Intervention (Drug)
- GUB-UCN2
- Intervention (Drug)
- Placebo
- Lead sponsor
- Gubra A/S
Record details
- Record id
cardio:ct-nct07702890- Content hash
283721dde31acb7545451d6fa18729b90bd4b460ab61e98d31b1c1f5dd0e4cb3